Literature DB >> 24510383

Low dose of oleanolic acid protects against lithocholic acid-induced cholestasis in mice: potential involvement of nuclear factor-E2-related factor 2-mediated upregulation of multidrug resistance-associated proteins.

Pan Chen1, Hang Zeng, Yongtao Wang, Xiaomei Fan, Chenshu Xu, Rongrong Deng, Xunian Zhou, Huichang Bi, Min Huang.   

Abstract

Oleanolic acid (OA) is a natural triterpenoid and has been demonstrated to protect against varieties of hepatotoxicants. Recently, however, OA at high doses was reported to produce apparent cholestasis in mice. In this study, we characterized the protective effect of OA at low doses against lithocholic acid (LCA)-induced cholestasis in mice and explored further mechanisms. OA cotreatment (5, 10, and 20 mg/kg, i.p.) significantly improved mouse survival rate, attenuated liver necrosis, and decreased serum alanine aminotransferase, aspartate aminotransferase, and alkaline phosphatase; more importantly, serum total bile acids and bilirubin, as well as hepatic total bile acids were also remarkably reduced. Gene and protein expression analysis showed that hepatic expression of multidrug resistance-associated protein 2 (Mrp2), Mrp3, and Mrp4 was significantly increased by OA cotreatment, whereas other bile acid metabolism- and transport-related genes, including Na+/taurocholate cotransporter, organic anion transporter 1b2, bile salt export pump, multidrug resistance protein 3, Cyp3a11, Cyp2b10, Sulfotransferase 2a1 (Sult2a1), and UDP-glucuronosyltransferase 1a1 (Ugt1a1), were only slightly changed. OA also caused increased nuclear factor-E2-related factor (Nrf2) mRNA expression and nuclear protein accumulation, whereas nuclear receptors farnesoid X receptor (FXR), pregnane X receptor (PXR), and constitutive androstane receptor were not significantly influenced by OA. Luciferase (Luc) assays performed in HepG2 cells illustrated that OA was a strong Nrf2 agonist with moderate PXR and weak FXR agonism. Finally, in mouse primary cultured hepatocytes, OA dose- and time-dependently induced expression of Mrp2, Mrp3, and Mrp4; however, this upregulation was abrogated when Nrf2 was silenced. In conclusion, OA produces a protective effect against LCA-induced hepatotoxicity and cholestasis, possibly due to Nrf2-mediated upregulation of Mrp2, Mrp3, and Mrp4.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24510383     DOI: 10.1124/dmd.113.056549

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  25 in total

1.  Oral administration of oleanolic acid, isolated from Swertia mussotii Franch, attenuates liver injury, inflammation, and cholestasis in bile duct-ligated rats.

Authors:  Jin Chai; Xiaohuang Du; Sheng Chen; XinChan Feng; Ying Cheng; Liangjun Zhang; Yu Gao; Shaoxue Li; Xiaochong He; Rongquan Wang; Xiangdong Zhou; Yong Yang; Weizao Luo; Wensheng Chen
Journal:  Int J Clin Exp Med       Date:  2015-02-15

Review 2.  Drug disposition alterations in liver disease: extrahepatic effects in cholestasis and nonalcoholic steatohepatitis.

Authors:  Mark J Canet; Nathan J Cherrington
Journal:  Expert Opin Drug Metab Toxicol       Date:  2014-07-03       Impact factor: 4.481

3.  Schisandrol B protects against acetaminophen-induced hepatotoxicity by inhibition of CYP-mediated bioactivation and regulation of liver regeneration.

Authors:  Yiming Jiang; Xiaomei Fan; Ying Wang; Pan Chen; Hang Zeng; Huasen Tan; Frank J Gonzalez; Min Huang; Huichang Bi
Journal:  Toxicol Sci       Date:  2014-10-14       Impact factor: 4.849

4.  p53-mediated regulation of bile acid disposition attenuates cholic acid-induced cholestasis in mice.

Authors:  Pan Chen; Dongshun Li; Yixin Chen; Jiahong Sun; Kaili Fu; Lihuan Guan; Huizhen Zhang; Yiming Jiang; Xi Li; Xuezhen Zeng; Xiao Chen; Min Huang; Huichang Bi
Journal:  Br J Pharmacol       Date:  2017-10-22       Impact factor: 8.739

5.  Effects of corilagin on alleviating cholestasis via farnesoid X receptor-associated pathways in vitro and in vivo.

Authors:  Fan Yang; Yao Wang; Gang Li; Juan Xue; Zhi-Lin Chen; Feng Jin; Lei Luo; Xuan Zhou; Qian Ma; Xin Cai; Hua-Rong Li; Lei Zhao
Journal:  Br J Pharmacol       Date:  2018-01-25       Impact factor: 8.739

Review 6.  Role of Nrf2 in chronic liver disease.

Authors:  Wei Tang; Yong-Fang Jiang; Murugavel Ponnusamy; Mamadou Diallo
Journal:  World J Gastroenterol       Date:  2014-09-28       Impact factor: 5.742

7.  Schisandrol B protects against cholestatic liver injury through pregnane X receptors.

Authors:  Hang Zeng; Yiming Jiang; Pan Chen; Xiaomei Fan; Dongshun Li; Aiming Liu; Xiaochao Ma; Wen Xie; Peiqing Liu; Frank J Gonzalez; Min Huang; Huichang Bi
Journal:  Br J Pharmacol       Date:  2017-03-16       Impact factor: 8.739

8.  ABCF2, an Nrf2 target gene, contributes to cisplatin resistance in ovarian cancer cells.

Authors:  Lingjie Bao; Jianfa Wu; Matthew Dodson; Elisa Montserrat Rojo de la Vega; Yan Ning; Zhenbo Zhang; Ming Yao; Donna D Zhang; Congjian Xu; Xiaofang Yi
Journal:  Mol Carcinog       Date:  2017-05-02       Impact factor: 4.784

9.  Preserved Gut Microbial Diversity Accompanies Upregulation of TGR5 and Hepatobiliary Transporters in Bile Acid-Treated Animals Receiving Parenteral Nutrition.

Authors:  Ajay Kumar Jain; Abhineet Sharma; Sumit Arora; Keith Blomenkamp; Ik Chan Jun; Robert Luong; David John Westrich; Aayush Mittal; Paula M Buchanan; Miguel A Guzman; John Long; Brent A Neuschwander-Tetri; Jeffery Teckman
Journal:  JPEN J Parenter Enteral Nutr       Date:  2016-08-20       Impact factor: 4.016

10.  Schisandrol B protects against acetaminophen-induced acute hepatotoxicity in mice via activation of the NRF2/ARE signaling pathway.

Authors:  Yi-ming Jiang; Ying Wang; Hua-sen Tan; Tao Yu; Xiao-mei Fan; Pan Chen; Hang Zeng; Min Huang; Hui-chang Bi
Journal:  Acta Pharmacol Sin       Date:  2016-01-25       Impact factor: 6.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.